Crosstalk of T cells within the ovarian cancer microenvironment.

3D tumor models T cell cellular crosstalk ovarian cancer spatial omics tumor microenvironment

Journal

Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956

Informations de publication

Date de publication:
27 Sep 2024
Historique:
received: 28 06 2024
revised: 02 09 2024
accepted: 03 09 2024
medline: 29 9 2024
pubmed: 29 9 2024
entrez: 28 9 2024
Statut: aheadofprint

Résumé

Ovarian cancer (OC) represents ecosystems of highly diverse tumor microenvironments (TMEs). The presence of tumor-infiltrating lymphocytes (TILs) is linked to enhanced immune responses and long-term survival. In this review we present emerging evidence suggesting that cellular crosstalk tightly regulates the distribution of TILs within the TME, underscoring the need to better understand key cellular networks that promote or impede T cell infiltration in OC. We also capture the emergent methodologies and computational techniques that enable the dissection of cell-cell crosstalk. Finally, we present innovative ex vivo TME models that can be leveraged to map and perturb cellular communications to enhance T cell infiltration and immune reactivity.

Identifiants

DOI: 10.1016/j.trecan.2024.09.001 PMID: 39341696
pubmed: 39341696
pii: S2405-8033(24)00190-0
doi: 10.1016/j.trecan.2024.09.001
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests D.D.L. has received funding from Hoffmann-La Roche AG. The remaining authors declare no competing interests.

Auteurs

Bovannak S Chap (BS)

Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland.

Nicolas Rayroux (N)

Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland.

Alizée J Grimm (AJ)

Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland.

Eleonora Ghisoni (E)

Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland.

Denarda Dangaj Laniti (D)

Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland. Electronic address: Denarda.Dangaj@chuv.ch.

Classifications MeSH